Celularity Inc — Investor Relations & Filings

Celularity Inc. is a clinical and commercial-stage biotechnology company specializing in cellular and regenerative medicine. The company develops and commercializes therapies derived from the postpartum human placenta. Its core focus is on creating off-the-shelf, allogeneic cell therapies, including genetically modified and unmodified Natural Killer (NK) cells, CAR T-cells, and mesenchymal-like adherent stromal cells (MLASCs). These therapeutic programs target a range of conditions, including cancer, immune disorders, and aging-related degenerative diseases. In addition to its clinical pipeline, Celularity markets a suite of commercial placenta-derived biomaterial products. The company leverages the unique biological properties of the placenta to develop accessible treatments for significant unmet medical needs.